Use of a multi-gene pharmacogenetic panel reduces adverse drug effects

Larisa H Cavallari; Julie A Johnson

doi:10.1016/j.xcrm.2023.101021

Use of a multi-gene pharmacogenetic panel reduces adverse drug effects

Cell Rep Med. 2023 May 16;4(5):101021. doi: 10.1016/j.xcrm.2023.101021. Epub 2023 Apr 20.

Authors

Larisa H Cavallari¹, Julie A Johnson²

Affiliations

¹ Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy University of Florida, Gainesville, FL, USA. Electronic address: lcavallari@cop.ufl.edu.
² Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy University of Florida, Gainesville, FL, USA; Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, FL, USA.

Abstract

Swen et al.¹ examine the utility of multi-gene pharmacogenetic testing in a large multi-national cohort. They show fewer adverse drug reactions among patients receiving testing and prescribing recommendations based on genotype results compared with those receiving usual care.

Publication types

Research Support, N.I.H., Extramural
Comment

MeSH terms

Drug-Related Side Effects and Adverse Reactions* / genetics
Drug-Related Side Effects and Adverse Reactions* / prevention & control
Genotype
Humans
Pharmacogenetics* / methods
Pharmacogenomic Testing / methods

Grants and funding

U01 HG007269/HG/NHGRI NIH HHS/United States